The observed synergistic effect of Palbociclib with HMGB2 inhibition suggests that combining HMGB2 modulation with cell cycle inhibitors could provide a promising strategy to enhance the efficacy of current cancer therapies, particularly in female-specific cancers where HMGB2 is implicated in tumor progression. Here, HMGB2 is linked to neoplasm.